CNSide Diagnostics, a subsidiary of Plus Therapeutics, presented data on the CNSide Cerebrospinal Fluid (CSF) Assay Platform at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting on November 21, 2024. The data showcased the assay's utility in identifying mutations of key biomarkers in the CSF.
The CNSide CSF Assay analyzed 258 CSF samples across 66 leptomeningeal metastases (LM) patients at five institutions. This analysis identified extensive, actionable mutational changes and clinically relevant longitudinal biomarkers.
The data suggests that biomarker mutation profiles in LM are dynamic, offering valuable insights for treatment strategies. This highlights the potential of CNSide to inform and improve clinical management decisions for LM patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.